Literature DB >> 11579204

Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids.

H R Kast1, C M Nguyen, C J Sinal, S A Jones, B A Laffitte, K Reue, F J Gonzalez, T M Willson, P A Edwards.   

Abstract

The farnesoid X-activated receptor (FXR; NR1H4), a member of the nuclear hormone receptor superfamily, induces gene expression in response to several bile acids, including chenodeoxycholic acid. Here we used suppression subtractive hybridization to identify apolipoprotein C-II (apoC-II) as an FXR target gene. Retroviral expression of FXR in HepG2 cells results in induction of the mRNA encoding apoC-II in response to several FXR ligands. EMSAs demonstrate that recombinant FXR and RXR bind to two FXR response elements that are contained within two important distal enhancer elements (hepatic control regions) that lie 11 kb and 22 kb upstream of the transcription start site of the apoC-II gene. A luciferase reporter gene containing the hepatic control region or two copies of the wild-type FXR response element was activated when FXR-containing cells were treated with FXR ligands. In addition, we report that hepatic expression of both apoC-II and phospholipid transfer protein mRNAs increases when mice are fed diets supplemented with cholic acid, an FXR ligand, and this induction is attenuated in FXR null mice. Finally, we observed decreased plasma triglyceride levels in mice fed cholic acid- containing diets. These results identify a mechanism whereby FXR and its ligands lower plasma triglyceride levels. These findings may have important implications in the clinical management of hyperlipidemias.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579204     DOI: 10.1210/mend.15.10.0712

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  76 in total

Review 1.  Human CYP7A1 deficiency: progress and enigmas.

Authors:  Anne Beigneux; Alan F Hofmann; Stephen G Young
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 2.  Role of bile acids in the regulation of the metabolic pathways.

Authors:  Hiroki Taoka; Yoko Yokoyama; Kohkichi Morimoto; Naho Kitamura; Tatsuya Tanigaki; Yoko Takashina; Kazuo Tsubota; Mitsuhiro Watanabe
Journal:  World J Diabetes       Date:  2016-07-10

3.  SIRT1 enzymatically potentiates 1,25-dihydroxyvitamin D3 signaling via vitamin D receptor deacetylation.

Authors:  Marya S Sabir; Zainab Khan; Chengcheng Hu; Michael A Galligan; Christopher M Dussik; Sanchita Mallick; Angelika Dampf Stone; Shane F Batie; Elizabeth T Jacobs; G Kerr Whitfield; Mark R Haussler; Michael C Heck; Peter W Jurutka
Journal:  J Steroid Biochem Mol Biol       Date:  2017-06-19       Impact factor: 4.292

4.  Bile acids alter the subcellular localization of CNT2 (concentrative nucleoside cotransporter) and increase CNT2-related transport activity in liver parenchymal cells.

Authors:  Sonia Fernández-Veledo; Isabel Huber-Ruano; Ivette Aymerich; Sylvie Duflot; F Javier Casado; Marçal Pastor-Anglada
Journal:  Biochem J       Date:  2006-04-15       Impact factor: 3.857

5.  Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice.

Authors:  Yanqiao Zhang; Florence Ying Lee; Gabriel Barrera; Hans Lee; Charisse Vales; Frank J Gonzalez; Timothy M Willson; Peter A Edwards
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-12       Impact factor: 11.205

6.  Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice.

Authors:  Helen B Hartman; Stephen J Gardell; Chris J Petucci; Shuguang Wang; Julie A Krueger; Mark J Evans
Journal:  J Lipid Res       Date:  2009-01-27       Impact factor: 5.922

Review 7.  The Farnesoid X Receptor (FXR) as modulator of bile acid metabolism.

Authors:  Folkert Kuipers; Thierry Claudel; Ekkehard Sturm; Bart Staels
Journal:  Rev Endocr Metab Disord       Date:  2004-12       Impact factor: 6.514

8.  FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver.

Authors:  Romeo Papazyan; Xueqing Liu; Jingwen Liu; Bin Dong; Emily M Plummer; Ronald D Lewis; Jonathan D Roth; Mark A Young
Journal:  J Lipid Res       Date:  2018-03-20       Impact factor: 5.922

9.  Mechanisms of triglyceride metabolism in patients with bile acid diarrhea.

Authors:  Nidhi Midhu Sagar; Michael McFarlane; Chuka Nwokolo; Karna Dev Bardhan; Ramesh Pulendran Arasaradnam
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

10.  Bile acid sequestrants for lipid and glucose control.

Authors:  Bart Staels; Yehuda Handelsman; Vivian Fonseca
Journal:  Curr Diab Rep       Date:  2010-02       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.